Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2014-04-30 | Michael S. Perry, Ph.D. 55 Director ...The audit committee consists of Jeremy Curnock Cook, Louis Drapeau and Michael S. Perry. The compensation committee consists of Jeremy Curnock Cook, Louis Drapeau and Michael S. Perry. The nominating and corporate governance committee consists of Jeremy Curnock Cook, Louis Drapeau and Michael S. Perry. Non-executive director compensation table: Michael S. Perry, Ph.D. $39,750 |
| 2014-11-25 | Michael S. Perry, Ph.D. Includes options to purchase 153,000 shares of common stock. |
| 2015-07-10 | Michael S. Perry has served as a member of our Board of Directors since November 2005. Dr. Perry is currently Global Head of Stem Cell Therapy and Vice President of the Integrated Hospital Care Franchise for Novartis Pharmaceuticals Corporation. |
| 2016-05-20 | The following table sets forth information for our current directors: Name Age Position Michael S. Perry, Ph.D. 56 Director |
| 2017-07-24 | Michael S. Perry, Ph.D. has served as a member of our Board of Directors since November 2005. ... Our Audit Committee consists of Louis Drapeau, Michael S. Perry and Vijay Samant. ... The Board of Directors has an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. ... The following table and related footnotes show the compensation paid during the year ended December 31, 2016 to our non-employee directors, other than Ms. Johnson whose 2016 compensation is set forth above under Executive Compensation above. ... Michael S. Perry 59,000 |
| 2018-11-09 | Michael S. Perry, D.V.M., Ph.D. has served as a member of our Board of Directors since November 2005. Since June 2017 Dr. Perry has served as the Chief Executive Officer of Avita Medical Ltd, a publicly traded (ASX:AVH) medical technology company, and has been a member of the board of directors of Avita Medical since February 2013. ... The Nominating and Corporate Governance Committee and the Board of Directors believe that Dr. Perry’s substantial scientific and medical knowledge, investing experience, and operational and executive experience in the biotechnology and pharmaceutical industries qualifies him to serve on our Board of Directors. |
Data sourced from SEC filings. Last updated: 2026-02-03